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Background: Friedreich’s Ataxia (FRDA) is a neurodegenerative disorder that causes progressive damage to the
central and peripheral nervous systems having a significant impact upon quality of life. With little information in the
literature, cross-sectional observational studies were conducted in the UK and Germany to collect data on resource
use and the burden of the disease on individuals and their caregivers.
Methods: Cross-sectional observational studies were conducted in the UK and Germany to estimate the burden of
FRDA on individuals and on the respective healthcare systems. A total of 75 individuals in the UK and 28 in
Germany were recruited to the study. Participants in both countries were asked to complete a Patient and
Caregiver Information Form (PCIF), regarding access to, and use of, healthcare resources, and the impact FRDA has
on their lifestyle. In Germany, doctors were asked to complete a Patient Record Form (PRF). Analyses of annual
direct and indirect resource utilization were conducted for both countries while costs were calculated for the UK
only. These figures were compared to the costs associated with Parkinson’s disease; one of the most common
neurodegenerative conditions and the one most similar in terms of disease progression.
Results: The results showed that the annual burden of FRDA is significant and falls on the health and social care
sectors, on society, on caregivers and on the individuals themselves. In the UK FRDA had a total annual cost per
person of between £11,818 and £18,774 depending on whether the cost of long-term unemployment was
included.
Typically the largest component of direct costs is associated with professional care. Given the high proportion of
children and young adults recruited and the long disease duration, (typically 40-50 years for FRDA, compared with
20 years for Parkinson’s disease), these figures may underestimate the true burden of the disease.
Conclusion: It is hoped that these estimates of resource utilization, can help in understanding the previously
unquantified burden of FRDA. Given the long disease duration, management strategies should seek to minimise
the impact of the condition on individuals and their caregivers, while maximising quality of life.
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Friedreich’s Ataxia (FRDA) is an autosomal recessive
neurodegenerative disorder that causes progressive dam-
age to both the central and peripheral nervous systems.
Although rare, it is the most frequent of the inherited
ataxias, with an estimated prevalence in Europe of 1 in
50,000 [1]. FRDA is caused by mutations in the gene en-
coding the protein frataxin on chromosome 9q13, most
commonly in the form of a GAA expansion within the
first intron of the gene, which causes decreased produc-
tion of frataxin [2]. Current evidence suggests that a loss
of frataxin causes iron overload in mitochondria and an
increase in free-radical production leading to oxidative
damage and inactivation of mitochondrial respiratory
chain enzymes, particularly complexes I, II, III and
aconitase [3].
FRDA is characterized by progressive gait and limb
ataxia, dysarthria, dysphagia, abnormal eye movements,
hearing problems, sensory loss, muscular weakness, are-
flexia and extensor plantar responses. Non-neurological
features include scoliosis, foot deformity, hypertrophic car-
diomyopathy and diabetes mellitus [4]. Symptom onset
typically occurs in childhood or adolescence, although late-
onset cases are described. Life expectancy is around 40–50
years [3-5].
The management of individuals with FRDA requires a
multidisciplinary approach. Most people diagnosed with
the disorder require mobility aids such as a cane, walker
or wheelchair by their teens or early 20s, and may re-
quire surgery for scoliosis or foot deformities [6]. Regu-
lar follow-up with annual echocardiograms and blood
tests are necessary to detect and monitor the develop-
ment of cardiac involvement and diabetes. Because of
the progressive and disabling neurological and other
features of the condition, FRDA has a significant impact
upon quality of life [7].
Little or no data are available in the literature on the
burden of FRDA on individuals with the condition, their
families, caregivers, or society. More specifically, there is
no record of previous investigations into resource util-
isation by patients with FRDA. To address this gap
the current questionnaire-based studies were conducted
to collect information on the treatment and care of
individuals with FRDA in the UK and Germany, and the
burden of the disease on these individuals and their
caregivers. Secondary objectives included a comprehen-
sive description of people with FRDA (including their
symptoms, diagnostic information and demographics),
analysis of current management practices and treatment
patterns.
Finally we compared the Cost of Illness (COI) of FRDA
with Parkinson’s disease, one of the most common
neurodegenerative conditions and one with similarities in
terms of symptoms and progression of the disease [8].Methods
Study design
Cross-sectional observational studies were conducted in
the UK and Germany to estimate the burden of FRDA
on individuals with the condition and on the respective
healthcare systems. Participants in both countries were
asked to complete a Patient and Caregiver Information
Form (PCIF), regarding access to, and use of, healthcare
resources, and the impact FRDA has on their lifestyle.
The PCIF was jointly developed by Adelphi Real World
(ARW) and Takeda with additional scientific input being
provided by Takeda, Ataxia UK and a leading German
Neurologist with a special interest in neurodegenerative
and hereditary movement disorders. In addition, the
PCIF was reviewed by a patient with FRDA in terms of
the form’s ease of use, layout and font size, and the ap-
propriateness of the questions/language used. All ques-
tions in the PCIF were closed questions.
For the purposes of this study, participants were
considered to be children if aged 17 years and under,
and adult if aged 18 years or over. In terms of who
completed the PCIF, the parent or the child, children
were encouraged to complete the form, with parental as-
sistance if necessary. For very young children, the parent
completed the form on their behalf. For individuals not
capable of completing the PCIF, their caregivers were
asked to complete selected sections of the questionnaire
on their behalf.
Included in the PCIF were questions on patient
demographics, FRDA medical history, healthcare re-
source utilization (hospitalizations, surgical procedures,
consultation frequency, medications etc), loss of patient
and caregiver productivity (Work and Productivity
Impairment Index questionnaire – WPAI [9], the use of
aids and adaptations, together with the impact FRDA
has on their quality of life. In addition, patients were
asked to provide details of the cost of any modifications
made to their living accommodation, and how these
modifications were paid for.
In the UK, individuals with the condition were rec-
ruited through the ataxia patient association, Ataxia UK,
while in Germany, individuals were recruited by their
physician. In the UK, Ataxia UK posted PCIFs to 200
patients randomly selected from Ataxia UK’s database,
along with an introductory letter and patient informa-
tion sheet explaining the study.
In Germany, a total of 25 neurologists were approached
to take part in the study, of whom 5 agreed to participate.
These 5 neurologists working in specialist centres in
Göttingen, Munich, Freiburg, Bonn and Essen, were asked
to complete a Patient Record Form (PRF), using informa-
tion collected from the medical record, for individuals
with FRDA who had been under their supervision for at
least two years. Included in the physician completed PRFs
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tory, Friedreich’s Ataxia Rating Scale [10] score, activities
of daily living, diagnostic tests, symptoms and medication
history. Having completed the PRF, the neurologists were
asked to post a corresponding PCIF, together with an in-
struction sheet, to each patient they included in the study
so that the physician and patient-reported data could
be linked. As in the UK study, no sensitive data were
collected.
In Germany, information on direct medical resource
use was provided by the physician as well as the par-
ticipant. Information on diagnostic procedures was
provided by the physician. Information on direct non-
medical resources (such as aids and adaptations) was
collected from participants only. Both physician and
participants were asked to provide details on respite
care. Where information was supplied by both the phys-
ician and participant, data were collected from the med-
ical record as these were deemed more reliable than
those from participant recollection. For both the UK and
Germany, consent was implicit in the return of the
surveys.
In terms of the recall period, with the exception of
questions such as “had they ever had surgery” or “did
they use mobility and/or other aids”, the recall period
was 12 months. The recall period for work productivity
was 7 days as this is the stated recall period for the
Work Productivity and Activity Impairment (WPAI)
tool.
The data were collated and analysed using STATAW
Version 10 (StataCorp LP, College Station, USA) and
SPSSW Version 15 (SPSS Inc., Chicago, USA). As sample
sizes were low in both the UK (n=75) and Germany
(n=28), qualitative (i.e. the reporting of frequencies and
percentages) rather than quantitative statistics, were
conducted.
Resource utilization can be analysed from a number of
perspectives. In this analysis, annual direct and indirect
resource utilization and costs were calculated for the UK
only. For the German study, analyses were conducted on
direct and indirect resource utilization.
In terms of resource utilization, the following were
considered in the analysis:
 Patient visits to various Health Care Professionals
(HCPs) (neurologists, primary care physicians
(PCPs), physiotherapists, nurses etc.) in the previous
12 months.
 Individuals with FRDA hospitalized in the previous
12 months for medical or surgical procedures.
 Diagnostic tests performed on patients in the
previous 12 months (Germany only).
 Current medication – prescription and non-
prescription. Modifications made by individuals with FRDA to
their living accommodation.
 Mobility aids used by individuals with FRDA.
 Short-term or respite care used by individuals with
FRDA.
 Formal and informal caregiving provided by
professionals and caregivers related to the patient.
 For patients currently in employment/education,
work/teaching-time missed as a consequence of FRDA.
 Patients currently unemployed or on benefit.UK cost of illness
A bottom-up cost of illness methodology was employed;
calculating costs on an individual basis before aggregat-
ing a total cost.
Costs were analysed in three main categories: (i) dir-
ect costs, (ii) costs associated with productivity and
work loss and (iii) non-recurring (capital expenditure)
costs. Direct costs were again divided into direct
medical and other (non-treatment) direct costs. Direct
medical costs included outpatient and community
consultation costs, surgical and hospitalization costs,
health-related service costs and medication costs, (in-
cluding where appropriate, the cost of non-prescribed
drugs). Other direct costs included social and respite
care, and other non-treatment costs. Longer term costs
such as mobility assistance and adaptations to living
accommodation, realized over a number of years, were
depreciated according to standard accountancy practices.
Unit cost data were obtained from published UK
sources and applied to respondent estimates of resource
use. Hospitalization costs were taken from the National
Schedule of Reference Costs Year: '2008-09' - NHS Trusts
Elective Inpatient HRG Data [11], while unit costs for out-
patient consultations were taken from “Unit cost of health
and social care” published by the PSSRU, University of
Canterbury, UK 2009 [12]. Drug costs were sourced from
the British National Formulary Number 59 [13].
Indirect costs included a loss of productivity asso-
ciated with individuals with FRDA and their caregivers
caused by absenteeism, an inability to work due to
FRDA, and caregivers having to reduce their working
hours.
A human capital approach was used to calculate prod-
uctivity losses arising from reduced working time or
caregiving whereby the mean time lost was multiplied by
the average daily wage and by the number of working
days per year (taken to be 220) in order to extrapolate to
an annual cost. The average weekly income in the UK
was taken to be £456 per week (Office for National
Statistics, Labour Market Statistics, June 2010), which
equates to an average daily income of £91.20 or £12.16
per hour assuming a 7.5 hour working day.
Table 1 Demographics and socioeconomic characteristics




Mean Age (years) ± SD 32 ± 18 28 ± 14











Adults (aged >18 years) 50 (67%) 20 (71%)
Children (aged <18 years) 25 (33%) 8 (29%)
n=75 n=28





































Employment status (% employed
full time)
5 (7%) 4 (13%)
n=74 n=32*
Unemployed due to FRDA 22 (30%) 8 (25%)
n=74 n=32*
1Source UK – PCIF.
2Source Germany – PCIF.
*Multiple responses.
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For the UK, approval was sought and obtained from
Welwyn Clinical Pharmacology Ethics Committee to
ensure the project met required ethical standards.
In Germany, ethical approval was obtained from the
Ethical Committee of Göttingen or from the participat-
ing centre’s local ethics committees.
Results
In the UK, questionnaires were sent to 200 individuals
with FRDA. A total of 75 questionnaires were returned,
with all 75 questionnaires being suitable for analysis; an
overall response rate of 38%. In Germany, Neurologists
at 5 centres (Gottingen, Munich, Freiburg, Bonn and
Essen) agreed to participate in the study, providing in-
formation on a total of 28 individuals with FRDA.
Demographic and socio-economic characteristics
The demographics and socio-economic characteristics
of the study population are summarised in Table 1. The
mean age of respondents was 32 ± 18 years (range 8-71)
in the UK and 28 ± 14 years (range 8-56) in Germany.
Sixty-seven percent of participants in the UK were
adults aged 18 years and above, compared with 71% in
Germany. Fifty-three percent in the UK and 61% in
Germany lived with their parents while 35% and 34%
respectively were in full time education. A higher pro-
portion of female participants (52% in the UK and 64%
in Germany) were recruited to the study. In Germany,
the proportion of participants in full time employment
was almost twice that of the UK (13% compared with
7%), while 30% of the study population were un-
employed due to FRDA in the UK compared to 25% in
Germany.
Symptoms
The mean age of symptom onset was 14.1 ± 11.3 years
(range 2-63 years) and 11.3 ± 6.1 years (range 4-28
years) in the UK and Germany respectively. In the UK,
46% of individuals with FRDA first experienced
symptoms as children aged up to 10 years, 39% in their
teenage years and 10% aged between 21 and 30. In the
UK, only 5% of respondents first experienced after their
30th birthday. In Germany, 43% first experienced FRDA-
related symptoms as children aged up to 10 years, 43%
as teenagers and 7% after their 21st birthday. (Note - 7%
of individuals in Germany did not know when they first
experienced symptoms of FRDA The mean time from
symptom onset to first doctor visit was 1.6 ± 3.1 years
(range 0-19 years) in the UK and 2.0 ± 3.1 years (range
0-10 years) in Germany. The time from first doctor visit
to diagnosis was 2.7 ± 3.7 years (range 0-20 years) in the
UK and 1.9 ± 2.3 years (range 0-8 years) in Germany.With participants being asked to record all FRDA-
related symptoms experienced over the previous 12
months, the results (Table 2) show participants
experienced a range of symptoms linked to their condi-
tion including: stability and coordination problems, gait
ataxia, scoliosis, foot and eye problems, fatigue, anxiety
and depression, speech and swallowing difficulties, car-
diac problems and diabetes.
Resource utilization in United Kingdom
In terms of health care resource utilization, a total of 17
UK participants (23%) had been hospitalized in the
Table 2 Participant reported symptoms experienced in





Gait / Posture symptoms
Problems with lower limb
coordination
73 (97%) 23 (82%)
Muscle weakness (upper or lower
limbs)
68 (91%) 17 (61%)
Problems with upper limb
coordination
70 (93%) 18 (64%)
Gait Ataxia (off balance when
walking)
60 (80%) 18 (64%)
Body sway when standing 63 (84%) 13 (46%)
Problems with standing upright 60 (80%) -
Muscle wasting (upper or lower
limbs)
56 (75%) 17 (61%)
Problems with sitting upright 55 (73%) -
Foot problems/deformities 50 (67%) 15 (54%)
Scoliosis (curved spine) 46 (46%) 20 (71%)




Fatigue 65 (87%) 21 (75%)
Slowness and slurring of speech 62 (83%) 19 (67%)
Problems with swallowing 51 (68%) 0
Anxiety 39 (52%) 10 (35%)
Depression 37 (49%) 7 (25%)
Problems with eye movements 43 (57%) 8 (28%)
Palpitations 31 (41%) 6 (21%)
Heart enlargement 24 (32%) 9 (32%)
Other heart problems 15 (20%) 5 (17%)
Difficulty breathing 26 (35%) 6 (21%)
Loss of hearing 25 (33%) 6 (21%)
Loss of sight 22 (29%) 7 (25%)
Diabetes 9 (12%) 4 (14%)
Heart failure 5 (7%) 2 (7%)
1Source UK – PCIF.
2Source Germany - PCIF.
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ber of admissions was 2.6 (range 1-10 admissions) and
the mean length of stay was 9.3 days. Respondents were
asked to provide the reason for the most recent admis-
sion. Of the 15 people who provided a reason, three
people were admitted for cardiovascular reasons, and
three for diagnostic examinations.
Respondents were also asked to state the reason for
admission for any previous hospitalizations within the
last 12 months. Of the 40 responses, the most com-
mon reasons for admission were cardioversion (12.5%),
ECG / echocardiogram (7.5% each), and routine heartexamination / stabilization of diabetes (5% each). In all,
heart related admissions (not diabetes) accounted for 16
of the 40 admissions (40%).
In terms of surgical procedures, although none of the
respondents had undergone foot surgery in the previous
12 months, 7 (9%) had had foot surgery at some time.
One patient reported having had spinal surgery (on two
separate occasions), while 10 (13%) reported having had
spinal surgery at some time.
Respondents had an average of 14.12 consultations
with health care professionals during the 12 month
period; 5.09 consultations with doctors and 9.03 with
other health care professionals. The most frequently
consulted doctors were neurologists (61%), followed by
cardiologists (57%) and PCPs (48%). The mean number
of consultations over the same period was 4.37 for PCPs,
but only 1.55 and 1.34 for cardiologists and neurologists
respectively. With regards to other health care pro-
fessionals, the majority of consultations occurred with
physiotherapists, nurses and occupational therapists with
an average of 7.77, 3.95 and 2.94 consultations per
annum respectively (Table 3).
In terms of medications, 50% of responders took an
average of 2.97 prescribed medicines and 21% purchased
an average of 3.2 non-prescribed medications. Table 4
illustrates the most commonly prescribed and non-
prescribed medications in the UK. Ten people (27%)
were prescribed idebenone, and a further 2 people (14%)
obtained it without prescription. Nine (24%) and 8 (57%)
individuals respectively were either prescribed or pur-
chased co-enzyme Q10, while a further 10 (27%) and 7
(50%) were either prescribed or purchased vitamin E.
Other commonly prescribed prescription drugs inclu-
ding: beta-adrenoreceptor blocking agents, skeletal muscle
relaxants and anti-epileptic drugs, were used by 24%, 19%
and 16% of respondents respectively. Fish oils (omega 3
fatty acids) and other nutritional supplements, were used
by 28% and 50% of respondents who purchased medi-
cations over the counter.
Table 5 illustrates the number of adults and children
taking idebenone and co-enzyme Q10. Of the 75 UK
respondents (25 children and 50 adults), 10 received
prescribed idebenone, of which, 9 (12%) were children.
Of those purchasing idebenone without prescription,
one was an adult (1.3%) and another was a child (1.3%).
Of the 9 people (12%) prescribed co-enzyme Q10, 6
(8%) were children and of those purchasing the drug, 3
(4%) were children and 5 (6.7%) were adults.
In terms of social care, 19 respondents (25%) received
formal care from a professional caregiver providing on
average 34.15 hours of care each week. Three people
with FRDA had experienced respite/short-term care in
the previous 6 months (averaging a total of 2.67
admissions per person with a mean stay of 3.5 days).
Table 3 Consultations with health care professionals in the previous 12 months
Consultations with HCPs
in the UK n (%)1
UK - Mean number of
consultations with HCPs1
Consultations with HCPs in
Germany n (%)2
Germany – Mean number of
consultations with HCPs2
Physicians
Neurologist 46 (61%) 1.34 17 (61%) 1.71
Cardiologist
(routine)
43 (57%) 1.55 17 (61%) 0.75
PCP 36 (48%) 4.37 17 (61%) 2.61
Orthopaedic
specialist
16 (21%) 1.37 13 (46%) 0.93
Paediatrician 17 (23%) 2.47 4 (14%) 0.54




39 (52%) 2.94 10 (36%) 11.79
Physiotherapist 35 (47%) 7.77 23 (82%) 28.07
Nurse
practitioner
21 (28%) 3.95 1 (4%) 0.14
Speech
therapist
17 (23%) 2.76 7 (25%) 9.93
Pharmacist 9 (12%) 7.22 14 (50%) 3.43
UK and Germany Compared.
1Source UK – PCIF.
2Source Germany - PRF.
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higher education, of whom 25 (21 children and 4 adults)
required special educational support in the form of a
classroom helper, a home tutor, a person to push their
wheelchair or additional educational assistance.
Sixty-one percent of respondents had modified their liv-
ing accommodation to ease the burden of FRDA. While
extensive home improvements were the most expensive at
an average of ₤33,166, the most common adaptations were
changes to facilitate bathing at a mean cost of ₤5,133, and
the provision of ramps at a mean cost of ₤2,564. The
mean cost of other adaptations included: the widening of
doors (£1,911), the installation of hoists (£1,684), electricTable 4 Most commonly prescribed and non-prescribed (inclu




Beta-adrenoreceptor blocking agents (Atenolol, Bisoprolol, Propranolol)
Skeletal muscle relaxants
Anti-epileptic drugs
Fish oils (Omega 3 fatty acids)
Other nutritional supplements (Multivitamins, minerals etc)
1Source UK – PCIF.beds (£1,758) and mattresses (£627), changes to the
flooring (£1,561), stair rails (£65) and a stair lift (£1,197)
(Table 6).
Funding for modifications to living accommodation
and mobility aids can come from a number of sources.
In the UK sources of funding included the National
Health Service (NHS), Social Services, charitable grants
and the respondents/families themselves. In terms of
living accommodation, 37% of total costs were reim-
bursed by Social Services with 26% being paid for by
the respondents themselves. Nine percent of costs
were reimbursed by the NHS and 3% by charities. In
contrast, the greatest proportion of costs related toding over the counter and other) drugs used by FRDA
Prescription drugs (n=37)1 Non-prescribed medication (n=14)1
n (%) n (%)
10 (27%) 2 (14%)
9 (24%) 8 (57%)






Table 5 Number of children and adult respondents taking Anti-Oxidants in the UK and Germany
Prescription drugs (UK)1 Non-prescription (UK)1 Prescription drugs (Germany)2 Non-prescription (Germany)3
Child Adult Child Adult Child Adult Child Adult
Idebenone 9 (12%) 1 (1.3%) 1 (1.3%) 1 (1.3%) 5 (17.9%) 1 (3.6%) 3* (10.7%) 1* (3.6%)
Co-enzyme Q-10 6 (8%) 3 (4%) 3 (4%) 5 (6.7%) 0 (0%) 1 (3.6%) 0 (0%) 0 (0%)
*For the same patients, physician stated as prescription medication.
n=75 for the UK (25 children and 50 adults).
n=28 for Germany (8 children and 20 adults).
1Source UK – PCIF.
2Source Germany – PRF.
3Source Germany - PCIF.
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Social Services, with respondents paying 33% them-
selves and charities 15%.
FRDA has an indirect cost that can be measured in an
individual’s productivity at, and absenteeism from, work
and the reduction in working hours required by the
caregiver to help the person with FRDA. Thirteen per-
cent of people with FRDA were in paid employment,
working a mean of 23.6 hours per week. The mean time
lost for those currently employed was 1 hour per week.
For those attending classes, they spent an average of
24.8 hours per week in class, and missed an average
of 3.9 hours. Seventy-seven percent of respondentsTable 6 Total cost and funding source for home modification
Modification Total cost (£) NHS (£) Social services
Adaptation bath/ shower 189,927 12,219 105,760
(6.4%) (55.7%)
Changes to home flooring 21,850 0 1,900
(8.7%)
Door Widening 34,408 1,775 17,431
(5.2%) (50.7%)
Electric bed 33,407 13,264 5,350
(39.7%) (16.0%)
Hand rail & Grab rail 1,277 290 697
(22.7%) (54.6%)
Hoist 32,000 5,600 25,600
(17.5%) (80%)
Ramps 76,933 4,433 49,967
(5.8%) (64.9%)
Specialized Mattress 9,400 5,400 600
(57.4%) (6.4%)
Stair Lift 5,985 1,500 995
(37.5%) (24.9%)
Stair rail 786 327 131
(41.7%) (16.7%)
Extensive home improvement 199,000 0 143,000
(71.9%)
1Source UK – PCIF.required caregiver support. Eight of the 58 caregivers
(14%) were professional caregivers. Twenty-nine percent
and 19% of caregivers were in full or part-time employ-
ment. Twenty-two percent of caregivers had had to take
time off work to care for the person with FRDA. On
average, caregivers had a mean time off work of 26.15
hours per week.Resource utilization in Germany
In Germany, 13 participants, or 46%, had been hospita-
lized for FRDA-related symptoms in the previous 12
months. The mean length of stay was 5.2 days.s and aids used by UK respondents1
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respondents had undergone foot surgery in the previous
12 months, 21% had had surgery in the past. Overall
15% (n=27) had had spinal surgery at some time.
The majority of participants (61%) had consulted a
neurologist in the previous 12 months, 61% a cardiolo-
gist, and 61% a PCP; seeing these doctors an average of
1.71, 0.75 and 2.61 times respectively. In terms of other
health care professionals, the majority of consultations
occurred with physiotherapists (82% of respondents),
followed by occupational therapists (36%) and speech
therapists (25%); seeing each an average of 28.07, 11.79
and 9.93 times respectively (Table 3).
Participants also provided details on health-related ser-
vice utilization including the type of service, total cost
and mode of reimbursement. Of the 28 participants, 6
(21%) reported using a health-related service. Eighty-
two percent of respondents visited a physiotherapist at
least once in the previous 12 months, but only 11% of
patients provided details on reimbursement. In terms of
health-related services, most were reimbursed by man-
datory health insurance or paid for by the respondent.
Of the 6 respondents who provided reimbursement
details for chiropody, hippotherapy, physiotherapy and
pilates, total costs equated to €1,445, of which 5% were
paid for by mandatory health insurance, 28% by private
health insurance and 67% by the respondent.
In terms of drug therapy, 64% of German participants
took prescribed medication for FRDA-related symptoms,
an average of 2.2 drugs per patient per annum. The most
commonly prescribed drugs were idebenone (33%), beta-
adrenoreceptor antagonists (22%), muscle relaxants (22%)
and non-steroidal anti-inflammatory drugs (NSAID’s)Table 7 Modifications to living accommodation made by Germ
Reim
Modification (n) Proportion Mandatory health insuran
n (%)
Adapted bath/shower (10) 63% 6 (60)
Bathroom alterations (4) 25% 3 (75)
Kitchen alterations (1) 6% 0
Adapted bed (4) 25% 3 (75)
Electric wheelchair (3) 19% 3 (100)
Handles/rails (7) 44% 4 (57)
Lifter/Hoist (5) 31% 5 (100)
Ramp (4) 25% 3 (75)
Speaking computer (1) 6% 1 (100)
Walking frame (1) 6% 1 (50)
Walking sticks (1) 6% 0
Wheel chair (3) 19% 2 (67)
Other* (7) 44% 1 (14)
* Adaptation to house, folding chair, mattress, special seat, cars.
1Source Germany – PCIF.(17%). Twenty-nine percent of participants reported uti-
lizing non-prescribed medications; purchasing an average
of 1.38 drugs for FRDA-related symptoms. The eight
drugs bought without prescription were idebenone,
Cranberola, Magnesium, L-carnitine, Cuprum Metallicum
D6, Plumbum D6, Captobeta and Ranitidine.
Neurological testing was conducted at least once on
all participants and included the Scale for the Assess-
ment and Rating of Ataxia (SARA), the International
Cooperative Ataxia Rating Scale (ICARS) and the
Friedreich’s Ataxia Rating Scale (FARS). In addition,
physicians conducted a number of diagnostic tests at
regular intervals. These tests included: blood pressure,
electrocardiograms, lipid profiles, echocardiograms, glu-
cose tests, HbA1c, liver and kidney function tests,
hearing and eye tests, spinal radiographs and MRI scans.
In terms of non-medical resource use, 7% of patients
had used short-term respite care in the previous 12
months and of the 12 in an academic setting, 8 received
special educational services. Sixteen participants (57%)
had modified their accommodation to support their daily
living. With a mean of 3.1 modifications per participant,
the most common adaptations were modifications to the
bath and shower facilities (63%), the fitting of handles/
handrails (44%) and the installation of a lifter/hoist
(31%) - (Table 7). With the source of funding for these
adaptations being reported by the respondents them-
selves, Table 8 shows a total cost of €7,252 for home
adaptations and aids excluding cars, (or €45,252 includ-
ing the cost of cars), of which the majority was met
through mandatory health insurance.
In terms of productivity lost in the previous 7 days,
employed participants missed an average of 1.9 hours ofan respondents1
bursement sources for home adaptations / aids






1 (10) 0 3 (30)
0 0 1 (25)
0 1 (100) 0
0 0 1 (25)
0 0 0
0 1 (14) 2 (29)
0 0 0
1 (25) 0 0
0 0 0
0 0 0
0 1 (100) 0
0 0 1(33)
0 1 (14) 5 (72)
Table 8 Total cost and funding source for home modifications and aids used by German respondents1
Modification Total cost (€) Mandatory health insurance (€) Private health insurance(€) Out-of-pocket (€) Not stated
Adapted bath/shower 135 43 29 15 48
Alteration of bath room 436 182 0 182 73
Alteration of kitchen 364 0 0 364 0
Adapted bed 800 600 0 0 200
Electric wheelchair 2,400 2,400 0 0 0
Handles/rails 54 33 0 2 20
Lifter 800 800 0 0 0
Ramp 239 216 23 0 0
Speaking computer 364 364 0 0 0
Walking frame 240 120 0 0 0
Walking sticks 120 0 0 120 0
Wheelchair 1,200 800 0 0 400
Mattress 100 0 0 100 0
Cars 38,000 0 0 0 38,000
Total (excluding cars) 45,252 5,557 52 902 38,741
(7,252) (5,557) (52) (902) (741)
1Source Germany – PCIF.
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hours of classes.
In terms of care, 60% of German participants required
caregiver support to complete their daily activities. Fifty
nine percent of all primary caregivers were the parents
(and in particular the mother - 80%), 18% were profes-
sional carers, 18% partners and 6% other relatives.
Caregivers per se provided a mean of 7 h of support each
week of which the individual’s partners provided 7 h, the
parent 4 h, other relatives 9 h and professional caregivers
16.7 h. Two caregivers reported having reduced theirTable 9 Total annual direct medical and non-medical costs of
Direct medical cost
Hospitalizations
Community / Outpatient Consultations
Prescription Medications
Non-prescription Medications





Total direct non-medical cost
Direct non-medical cost including long term adaptation and mobility c
Modification / Adaptation
Mobility
Total direct non-medical cost with long term costs
Total direct cost excluding modification and mobility costs
Total direct cost including modification and mobility costsworking hours by an average of 2.5 h per week in order
to provide care.
Annual cost of illness in United Kingdom
In terms of cost of illness (Table 9), the direct-medical
costs incurred in caring for the 75 individuals with FRDA
in the UK totaled £242,314 per annum. This figure, split
between hospitalization costs (£50,067), consultation costs
(£71,888), and medication costs (£120,359), gave a mean
cost per respondent of £3,230. Non-direct medical costs
of £322,940 per annum, were comprised of educationalFRDA in the United Kingdom (n=75)

















Table 11 Total Cost of Friedreich’s Ataxia (including long
term unemployment) in the United Kingdom (n = 75)
Cost Proportion of total cost
Direct Treatment Costs £242,314 17%
Direct Non-Treatment Costs £424,627 30%
Work Loss1 £741,079 53%
Total Cost £1,408,020
1 Work Loss sample size = 50 adults.
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professional caregiver costs (£304,668); averaging £4,306
per respondent. The total annual direct cost of caring for
people with FRDA was therefore £565,254 (mean cost
£7,537). Taking into account respondent reported ex-
penses including living accommodation modifications
(£44,268) and mobility aids (£57,419), the total annual dir-
ect non-medical cost of FRDA was £666,941.
Annual indirect costs resulting from a loss of respond-
ent and caregiver productivity were estimated at £4,426
and £214,989 respectively, a total of £219,415. Taking
into account potential work loss caused by respondents
being unable to work long-term, this estimated total cost
rose to £741,079 (Table 10).
Based on the responses received, FRDA resulted in a
total annual cost of between £886,356 and £1,408,020 in
the UK depending on whether the costs of long term
unemployment due to FRDA (£521,664) were included
or not (Tables 11 and 12). These equated to a cost per
person of £11,818 and £18,774 respectively.
Discussion
This study is the first to examine systematically the bur-
den of FRDA in the UK and Germany, encompassing
not only medical resource utilization, but also the bur-
den on respondents in terms of symptoms, the impact
on daily activities (including the need for mobility assist-
ance and modifications to accommodation), and the re-
quirement for caregiver support. The impact of caring
for people with FRDA was also assessed.
The results show that the annual burden of FRDA is
significant and falls on the health and social care sectors,
on society due to work loss, on caregivers and on the
individuals themselves. While the results of the UK COI
study show a mean cost of health care per person of
£3,230 per annum (including medications), this does not
reflect the true burden of FRDA. When non-health care
resource requirements (education, caregiver support etc)
are included, the cost significantly rises to an estimated
£7,537 per person. When indirect costs such as work
loss, mobility aids and accommodation modifications are
also taken into consideration, the estimated cost per per-
son rises to between £11,818 and £18,774, depending on
whether the costs of long-term unemployment or earlyTable 10 Total annual indirect costs of FRDA in the
United Kingdom (n = 50 adults)
Cost
Respondent related costs (time off work) £4,426
Respondent related costs (unable to work due to FRDA) £521,664
Caregiver related costs £214,989
Total costs excluding unemployment due to FRDA £219,415
Total costs including unemployment due to FRDA £741,079retirement due to FRDA are included in the calculation.
As direct health care costs represent such a small pro-
portion of total costs, focussing on these and excluding
the cost of long-term unemployment, would significantly
underestimate the true burden to society. The main
benefits of improved treatment options would be felt
from a societal perspective should the need for caregiver
support be reduced, if people were more able to partici-
pate in the workforce and if the need for modifications
to living accommodation were reduced.
In terms of resource utilization, 61% of participants
visited a neurologist in the UK and in Germany, while
47% and 82% visited a physiotherapist, and 48% and 61%
a PCP, (UK and Germany respectively).
In Germany, the proportion of patients admitted to
hospital for FRDA in the previous 12 months was twice
that in the UK (46% versus 23%). Similarly, the pro-
portion of participants who had had foot surgery at
some time was more than double that in the UK (21% ver-
sus 9%), while non-prescribed drug use for FRDA-related
symptoms was higher in the UK (3.2 versus 1.38 medi-
cations). The apparent difference in co-enzyme Q10 use
between the two countries is notable with just one
German patient taking co-enzyme Q10, compared with 17
(9 prescription and 8 OTC) in the UK. This difference
may in part be a consequence of a high dose co-enzyme
Q10/vitamin E trial having been conducted in the UK [14]
and may also reflect a bias in the UK sample of patients.
In general, patients willing to fill in questionnaires are
more willing to participate in research and therefore more
active in seeking therapeutic options.
Among the employed participants, mean work-time
lost per patient was higher in Germany than in the UK
(1.9 versus 1 hour per week), while the proportion of
UK caregivers who had had to take time off work was al-
most twice that of Germany (22% versus 12%).Table 12 Total cost of Friedreich’s Ataxia (excluding long
term unemployment) in the United Kingdom (n = 75)
Cost Proportion of total cost
Direct Treatment Costs £242,314 27%
Non-Treatment Costs £424,627 48%
Work Loss1 £219,415 25%
Total Cost £886,356
1 Work Loss sample size = 50 adults.
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be considered including the sample size. With 75 UK
and 28 German patients taking part in the study, it is
not possible to say whether they were representative of
the FRDA populations although, considering the rarity
of the condition, these sample sizes are considered
reasonable.
The differing means of recruitment should also be
taken into account. UK respondents could be more
highly motivated (since they were known to the patient
association and took the time to complete the question-
naire). While this is not a problem in itself, there is po-
tential to introduce bias if these patients were atypical in
terms of disease severity or in their ability to access
health and social care resources.
Similarly the methodological differences between the
two samples should be considered: whereas in the UK
respondents were asked to complete PCIFs from mem-
ory, in Germany, in addition to the PCIFs completed by
the patients, the recruiting physicians collected resource
use and diagnostic information on PRFs. No such
physician-reported, treatment-related data were collec-
ted in the UK study.
While patient recall is likely to be reasonable over the
last 3 months, it may be less accurate (especially for rou-
tine events) as the recall period increases. Exceptions are
major events such as hospitalizations and surgery, where
there is evidence to suggest recall is as good over longer
periods of time. While the recall periods specified in the
questionnaires were designed to reflect this, an element
of recall bias cannot be ruled out.
With no comprehensive studies in the literature, di-
rect comparisons are difficult. For this reason we have
chosen to compare the mean annual burden of FRDA
with that of Parkinson’s disease, one of the most com-
mon neurodegenerative conditions and one with similar-
ities in terms of symptoms and progression of the
disease [8].
Findley et al reported a higher mean annual burden for
advanced Parkinson’s disease of £28,700 [8], compared with
between £11,818 and £18,774 for FRDA. Of the £28,700,
£1,881 could be attributed to direct medical costs, £13,364
to direct non-medical costs and £12,454 to indirect infor-
mal care cost. Thirty-nine percent of advanced Parkinson’s
disease patients were hospitalized in the previous 12
months, compared with 23% of individuals with FRDA in
the UK and 46% in Germany. Parkinson’s disease patients
experienced an average of 1.6 admissions and 2.9 con-
sultations per year, while in the UK, individuals with FRDA
experienced 2.6 admissions and 14.1 consultations. In terms
of direct non-medical resources such as respite care, 13% of
Parkinson’s disease patients had used respite care in the
previous 12 months, compared with 5% of FRDA res-
ponders in the UK and 7% in Germany.Parkinson’s disease severity is measured using the
Hoehn and Yahr (H&Y) scale. All Parkinson’s disease
patients, regardless of disease severity, can experience
the OFF state. In the OFF state, individuals with
Parkinson’s disease can experience tremors, stiffness,
slowness of movement and/or periods of immobility.
This can be due to medication wearing off, or a reaction
to the medication itself, manifesting in a re-emergence
of symptoms.
Sixty-eight percent of people with Parkinson’s disease
reported in the study by Findley had a (H&Y) score of 3
or 4, spending between 0 and 25% of their waking time
in an OFF state (=OFF 1). As expected, disease progres-
sion was associated with an increase in carer hours from
5.4 professional and 34 informal carer hours/week for
OFF 1, to 21 professional and 51.25 informal care hours/
week for OFF IV.
In contrast to Findley’s study, where the average age of
individuals with Parkinson’s disease was 71.7 years, the
average age of individuals with FRDA was significantly
less at 32 years in the UK and 28 in Germany. With
more children and young adults in the early to mid-
stages of the disease, the cost of care is lower and may
well be hidden (with younger parents, individuals with
FRDA potentially have access to additional informal
unpaid support from relatives, teachers and other
caregivers). Given that Parkinson’s disease has a duration
of 20 years whereas FRDA has a duration of 40 to 50
years, the cost to society may well be greater than for
Parkinson’s disease.
In terms of future work, studies could include validat-
ing the PCIF for use in other countries and incorporat-
ing the use of the Friedreich’s Ataxia Impact Scale
(FAIS) [15]. Data from the FAIS could then be compared
to actual costs and burden of care to give an indication
of the impact of the disease. Similarly, collecting data on
clinical parameters such as the Friedreich’s Ataxia Rating
Scale (FARS) may provide an indication of the cost and
burden associated with disease severity.
Conclusions
In conclusion it can be seen that the annual burden of
FRDA is significant, falling on the health and social care
sectors, on society (due to work loss), on caregivers, and
on the individuals themselves. It is hoped that these
estimates of resource utilization, from both a health sec-
tor and societal perspective, can help in understanding
the previously unquantified burden of FRDA.
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